Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


War on C Difficile Is Being Fought On Multiple Fronts

Executive Summary

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.


Related Content

Lyme Disease Vaccine Pushes Valneva To US Listing
Full Steam Ahead At Ferring To Unlock Microbiome Potential For Reproduction
Vedanta Receives Cash Injection To Proceed With Microbiome-Derived Pipeline
'Slow Money As Bad As No Money' – SMEs Struggle For Superbug Funds
Microbiome Drug Development: An Investigation Into Challenges And Innovative Pipeline Approaches
No Safety Shortcuts Under Breakthrough Designation, Synthetic Biologics Finds


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts